- Home
- EVN vs VSTM Comparison
EVN vs VSTM Comparison
Compare EVN & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVN | VSTM |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.6M | 470.7M |
| IPO Year | 1998 | 2011 |
Fundamental Metrics
Financial Performance| Metric | EVN | VSTM |
|---|---|---|
| Price | $10.20 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.25 |
| AVG Volume (30 Days) | 96.0K | ★ 2.1M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $282.64 |
| Revenue Next Year | N/A | $72.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $9.59 | $4.01 |
| 52 Week High | $11.23 | $11.25 |
Technical Indicators
Market Signals| Indicator | EVN | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 45.30 |
| Support Level | $10.31 | $4.80 |
| Resistance Level | $11.15 | $6.79 |
| Average True Range (ATR) | 0.15 | 0.40 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 31.07 | 46.81 |
Price Performance
Historical ComparisonAbout EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.